title: Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast.
abstract: Invasive ductal carcinoma with lobular features (IDC-L) is not recognized as a distinct subtype of breast cancer, and its clinicopathologic features and outcomes are unknown. In this retrospective study, we focused on characterization of clinicopathologic features and outcomes of IDC-L and compared them to invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). 183 cases of IDC-L from 1996 to 2011 were compared with 1,499 cases of IDC and 375 cases of ILC. Available slides of IDC-L (n = 150) were reviewed to quantify the lobular component (≤ 20, 21-50, 51-80, >80 %), defined as small cells individually dispersed, arranged in linear cords, or in loose aggregates without the formation of tubules or cohesive nests. E-cadherin immunostain was performed to confirm ductal origin. Compared to IDC, IDC-L was more likely to have lower histologic grade (p < 0.001), be positive for estrogen receptor (96 vs. 70 %; p < 0.0001) and progesterone receptor (84 vs. 57 %; p < 0.0001), and less likely to overexpress HER-2/neu (12 vs. 23 %; p = 0.001). Despite these favorable prognostic features, IDC-L had a higher frequency of nodal metastases (51 vs. 34 %; p < 0.0001) and a worse 5-year disease-free survival than IDC (hazard ratio = 0.454; p = 0.0004). ILC and IDC-L had similar clinicopathologic features and outcomes. The proportion of the lobular component in IDC-L had no impact on the size, nodal status, stage, or outcome. Our data suggest that although IDC-L may be a variant of IDC, with >90 % of cases being E-cadherin positive, the clinical and biological characteristics are more similar to that of ILC.
authors.affiliation: Department of Pathology, University of Michigan Health System, 1500 E. Medical Center Dr., 2G340, Ann Arbor, MI 48109, USA.
authors.forename: David P
authors.initials: DP
authors.lastname: Arps
authors.forename: Patrick
authors.initials: P
authors.lastname: Healy
authors.forename: Lili
authors.initials: L
authors.lastname: Zhao
authors.forename: Celina G
authors.initials: CG
authors.lastname: Kleer
authors.forename: Judy C
authors.initials: JC
authors.lastname: Pang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D015820:Cadherins / Q000378:metabolism; D018270:Carcinoma, Ductal, Breast / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D018275:Carcinoma, Lobular / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008408:Mastectomy; D015412:Mastectomy, Segmental; D008875:Middle Aged; D060787:Neoplasm Grading; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D015820:Cadherins
references.citation: Am J Surg. 2012 Jul;204(1):66-77
references.pmid: 22178485
references.citation: Breast Cancer Res Treat. 2004 May;85(1):23-9
references.pmid: 15039595
references.citation: Histopathology. 1992 Jun;20(6):479-89
references.pmid: 1607149
references.citation: Cancer. 1994 Mar 15;73(6):1673-7
references.pmid: 8156495
references.citation: Arch Intern Med. 2003 Oct 13;163(18):2149-53
references.pmid: 14557212
references.citation: J Clin Oncol. 2008 Jun 20;26(18):3006-14
references.pmid: 18458044
references.citation: World J Surg Oncol. 2010 Apr 27;8:34
references.pmid: 20423478
references.citation: Breast Cancer Res Treat. 2009 Mar;114(2):243-50
references.pmid: 18404368
references.citation: JAMA. 2003 Mar 19;289(11):1421-4
references.pmid: 12636465
references.citation: Am J Surg. 2009 Oct;198(4):516-9
references.pmid: 19800459
references.citation: Histopathology. 1982 Mar;6(2):149-61
references.pmid: 7076138
references.citation: Breast Cancer Res. 2004;6(3):R149-56
references.pmid: 15084238
references.citation: Cancer. 1982 Nov 15;50(10):2163-9
references.pmid: 7127256
references.citation: J Surg Oncol. 1991 Sep;48(1):28-33
references.pmid: 1653879
references.citation: Ann Surg. 2000 Jun;231(6):877-82
references.pmid: 10816631
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):946-54
references.pmid: 16702375
references.citation: J Pathol. 1985 Jan;145(1):39-52
references.pmid: 2578561
references.citation: Ann Surg Oncol. 2010 Jul;17(7):1862-9
references.pmid: 20162457
references.citation: Lancet Oncol. 2006 Nov;7(11):910-8
references.pmid: 17081916
references.citation: World J Surg Oncol. 2010 Jun 21;8:51
references.pmid: 20565965
references.citation: Cancer. 1996 Jan 1;77(1):113-20
references.pmid: 8630916
references.citation: Surgery. 1993 Oct;114(4):637-41; discussion 641-2
references.pmid: 8211676
references.citation: Br J Cancer. 2005 Oct 31;93(9):1046-52
references.pmid: 16175185
references.citation: Surgery. 1982 Feb;91(2):234-40
references.pmid: 6277027
references.citation: Am J Clin Pathol. 2001 Jan;115(1):85-98
references.pmid: 11190811
references.citation: AJR Am J Roentgenol. 1989 Aug;153(2):265-71
references.pmid: 2750609
references.citation: Mod Pathol. 2001 Sep;14(9):836-41
references.pmid: 11557778